Europe
A platform trial is also efficient in that it enables the investigators to share placebo information.
Although a quiet week for COVID-19-related clinical trial announcements, there were plenty of others. Read on for more information.
Biogen reported that its gene therapy, cotoretigene toliparvovec, failed to hit the primary endpoint of the Phase II/III XIRIUS trial for X-linked retinitis pigmentosa (XLRP).
PerkinElmer expands its presence with the acquisition of Nexcelom, which would allow the company to expand global efforts to accelerate time to target and time to market for novel therapeutics.
Biopharma and life sciences companies strengthen their leadership teams and boards with Movers & Shakers.
Pivotal data from Amgen’s and AstraZeneca’s NAVIGATOR Phase III trial show tezepelumab, a potential first-in-class human monoclonal antibody, reduced asthma aggravations and exacerbations requiring hospitalizations better than placebo in patients with severe asthma.
Biopharma and life sciences from across the globe provide updates on their businesses and pipelines.
Two new venture capital funds, Droia Ventures and Perceptive Advisors closed on new funds to invest in early-stage life science companies.
Catch up on the investment news quickly with BioSpace’s brief overview of the biotech companies hitting the Nasdaq and raking in fresh cash the past week.
Sanofi’s troubles stemming from the 2019 recall of Zantac appear to be far from over.
PRESS RELEASES